Surface Oncology, Inc. (NASDAQ:SURF) has a beta value of 0 and has seen 553,661 shares traded in the last trading session. The company, currently valued at $322.97 Million, closed the last trade at $7.94 per share which meant it gained $0.22 on the day or 2.85% during that session. The SURF stock price is -29.09% off its 52-week high price of $10.25 and 82.62% above the 52-week low of $1.38. If we look at the company’s 10-day average daily trading volume, we find that it stood at 923.99 Million shares traded. The 3-month trading volume is 990.21 Million shares.
The consensus among analysts is that Surface Oncology, Inc. (SURF) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. None out of 6 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.4.
Surface Oncology, Inc. (NASDAQ:SURF) trade information
Sporting 2.85% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Nov 16 when the SURF stock price touched $9.00-1 or saw a rise of 11.78%. Year-to-date, Surface Oncology, Inc. shares have moved 322.34%, while the 5-day performance has seen it change -7.78%. Over the past 30 days, the shares of Surface Oncology, Inc. (NASDAQ:SURF) have changed -14.9%. Short interest in the company has seen 1.03 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 63.73% from current levels. The projected low price target is $11 while the price target rests at a high of $15. In that case, then, we find that the current price level is +88.92% off the targeted high while a plunge would see the stock lose 38.54% from current levels.
Surface Oncology, Inc. (SURF) estimates and forecasts
Figures show that Surface Oncology, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +65.07% over the past 6 months, with this year growth rate of -68.02%, compared to 10.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 29.8% and -150% for the next quarter. Revenue growth from the last financial year stood is estimated to be +151.8%.
Earnings growth for 2020 is a modest -495.1%.
Surface Oncology, Inc. (NASDAQ:SURF)’s Major holders
Insiders own 1.66% of the company shares, while shares held by institutions stand at 66.11% with a share float percentage of 67.22%. Investors are also buoyed by the number of investors in a company, with Surface Oncology, Inc. having a total of 72 institutions that hold shares in the company. The top two institutional holders are Atlas Venture Associates IX, LLC with over 4.65 Million shares worth more than $32.05 Million. As of September 29, 2020, Atlas Venture Associates IX, LLC held 11.42% of shares outstanding.
The other major institutional holder is VR Adviser, LLC, with the holding of over 3.88 Million shares as of September 29, 2020. The firm’s total holdings are worth over $26.76 Million and represent 9.53% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are USAA Mutual Fund Tr-Science & Technology Fund and Victory Portfolios-Victory RS Science & Technology Fund. As of July 30, 2020, the former fund manager holds about 2.6% shares in the company for having 1057296 shares of worth $5.51 Million while later fund manager owns 325.92 Thousand shares of worth $2.14 Million as of June 29, 2020, which makes it owner of about 0.8% of company’s outstanding stock.